Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
October 25 2023 - 8:45AM
Business Wire
- Oral abstract will be presented on Friday, November 3,
2023
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands, today
announced that Sue Ellen Cox M.D. will present final results from
the Phase 2 study evaluating the safety, efficacy and duration of
effect of 40U PrabotulinumtoxinA-xvfs at the 2023 American Society
for Dermatologic Surgery (ASDS) Annual Meeting on November 3, 2023,
in Chicago during an independent medical education session.
Oral Presentation
Information
Title: A Phase II, Randomized, Double Blind,
Active-Controlled, Increasing Dose Trial to Study the Safety and
Duration of Effect of 40U PrabotulinumtoxinA-xvfs in Glabellar
Lines: Final Results Time: 4:30 to 5:30 pm CT, Friday,
November 3, 2023
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving
the aesthetic neurotoxin market for the next generation of beauty
consumers through its unique, customer-centric business model and
innovative digital platform. Our mission is to become a global,
multi-product aesthetics company based on our flagship product,
Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the
brand name Nuceiva®. The product is manufactured in a
state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, a line
of five unique dermal fillers currently in late-stage development.
Visit us at www.evolus.com, and follow us on LinkedIn, Twitter,
Instagram or Facebook.
Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231024386212/en/
Investor Contact: Idalia Rodriguez,
Ned Mitchell Arbor Advisory Group Email: ir@evolus.com
Media Contact: Email:
media@evolus.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Apr 2023 to Apr 2024
